Navigation Links
Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
Date:11/21/2007

e three weeks. Brostallicin was escalated from 5 to 7 to 9 mg/m2 with a fixed dose of cDDP of 75 mg/m2. To review the poster for more detailed information, please go to http://www.CTICSeattle.com.

About Brostallicin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumors models. Brostallicin binds covalently to DNA within the DNA minor groove interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that

is currently being conducted by the European Organization for Research and Treatment of Cancer (EORTC).

About Systems Medicine (SM)

In July 2007, CTI acquired Systems Medicine (SM), a privately-held oncology company, in a stock-for-stock merger. SM applies a systems biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's 'context of vulnerability.' Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs -- the 'context of vulnerability'.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer mo
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Phase III Trial Finds Pharmaxis Bronchitol Effective
9. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
10. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , CHANGCHUN, China and LOS ANGEL...ongxin Pharmaceuticals, Inc. (OTC Bulletin Board: ...any,), a leading manufacturer, distributor and,ret...day announced it has,completed preparation for dis... , The Chinese government recently formal...
(Date:11/30/2009)..., , BOSTON and COPENHAGEN, Nov. 30 /PRN...Q") announced today that the Harvard Medical Schoo...en recognized as a MicroRNA Screening Center of Ex...d Medical School, and associated hospitals and ins...molecule and RNAi libraries. ,, MicroRNAs are a...
(Date:11/28/2009)..., The Vanuatu National Ad... its Second National Communication (SNC) Project i...rvices and CLIMsystems Ltd. of New Zealand have ge...ise results that will form the background for the ...s Framework Convention on Climate Change (UNFCCC)....
(Date:11/25/2009)..., , DURHAM, N.C., Nov. 25 /PRNewswi...veiled the first energy-efficient, single-treatmen... from carbon nanotubes to Andhra Pradesh, Minister... other leaders in Hyderabad, India today. Initial ... (IIT) Kanpur, confirmed that the majority of the ...
Breaking Biology Technology:China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India 2
... , NAVIGATE THIS ARTICLE: <A ... > <A , href="#3">RNA , ... href="#4">Electrophoresis, , ...>Hybridization, , Detection > <A ,... & Reprobing , , , , ...
... Gene arrays are solid supports upon which a ...ucleic acids have been placed at , ...t synthesis. In , array analysi... and then allowed to hybridize wi...on the array. (In the literature, the term "target...
... One of the RNA silencing , pr...hesis of siRNA, , the <A , ...?1620">Silencer <A , href="http://ww... Construction Kit . While this kit is ve...ral different sequences need to be made, it can be...
Other Biology Technology:Northern Analysis: The Basics 2Northern Analysis: The Basics 3Northern Analysis: The Basics 4Northern Analysis: The Basics 5Northern Analysis: The Basics 6Northern Analysis: The Basics 7Northern Analysis: The Basics 8Northern Analysis: The Basics 9Northern Analysis: The Basics 10Northern Analysis: The Basics 11Northern Analysis: The Basics 12Northern Analysis: The Basics 13Northern Analysis: The Basics 14Northern Analysis: The Basics 15Northern Analysis: The Basics 16Northern Analysis: The Basics 17Northern Analysis: The Basics 18Northern Analysis: The Basics 19Array Analysis: The Basics 2Array Analysis: The Basics 3Array Analysis: The Basics 4Array Analysis: The Basics 5Your Data: Silencing of a Pro-apoptotic Transcription Factor Using Synthetic siRNA 2Your Data: Silencing of a Pro-apoptotic Transcription Factor Using Synthetic siRNA 3
(Date:11/26/2009)...sistant Staphylococcus Aureus ) and other drug-re...mperature plasma prototype devices have been devel...ericidal cocktails. , Two prototype devices have... healthy skin (e.g. hands and feet) in hospitals a...threat; and another to shoot bacteria-killing agen...
(Date:11/25/2009)...roduced in the stomach, may be used to boost resis...disease, Yale School of Medicine researchers repor...ournal of Neuroscience . , Parkinson,s disease i...an area of the midbrain known as the substantia ni... Reduced production of dopamine in late-stage Par...
(Date:11/25/2009)...efighters, police officers and ambulance workers f... Center complex. They battled to save people from ..., tackled fires and evacuated as many people as th...7,000 people. And making their jobs even harder wa...orkers and their relatives jammed mobile networks ...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Hormone ghrelin can boost resistance to Parkinson's disease 2Magic box for mission impossible 2Magic box for mission impossible 3Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non Small Cell Lung Cancer T 55514 1Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non Small Cell Lung Cancer T 55514 2Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non Small Cell Lung Cancer T 55514 3Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non Small Cell Lung Cancer T 55514 4Weight Watchers 28R 29 Launches New Community on WeightWatchers com 55510 1Weight Watchers 28R 29 Launches New Community on WeightWatchers com 55510 2Weight Watchers 28R 29 Launches New Community on WeightWatchers com 55510 3AlphaRx Concludes GAI 122 Formulation Development Intended For The Prevention of Delirium 55507 1AlphaRx Concludes GAI 122 Formulation Development Intended For The Prevention of Delirium 55507 2
...e in repairing lung damage, according to a team of...ifferences to analyze the repair process in lung t... of the journal Transplantation, lead author Dani ...chool at Houston, and colleagues at the University...an 1 percent of a certain type of reparative lung ...
...limate statistics from the north Pacific Ocean and...Park. The University of Alberta doctoral student i...en the North Pacific Oscillation (NPO) and a mamma...n measurements, researchers are able to determine ...ive NPO translates into a milder climate in most o...
...d in the bone marrow and blood of mice can "restoc...s, according to new research published in this wee...ides direct evidence to overturn a long-held dogma...e egg cells only during fetal development and thus...s throughout life. The new report significantly ex...
Other Biology News:Candida albicans Genome Fully Annotated 2Candida albicans Genome Fully Annotated 3Ocean climate predicts elk population in Canadian Rockies 2Stem cells in bone marrow replenish mouse ovaries 2
Yeast Extract Solution from Invitrogen
(Miller's LB Broth Base) Luria Broth Base powder from Invitrogen
Bsg I from New England Biolabs
GIBCO Geneticin Selective Antibiotic liquid from Invitrogen
Biology Products: